Funding for this research was provided by:
Health Resources and Services Administration (UA3MC11054)
First Online: 16 February 2017
Compliance with Ethical Standards
: Dr. Veenstra-VanderWeele has consulted with Roche Pharmaceuticals, Novartis, and SynapDx and has had research funding from Roche Pharmaceuticals, Novartis, SynapDx, Seaside Therapeutics, Forest, and Sunovion. He receives an honorarium for editorial work from Springer and John Wiley and Sons. Dr. Anagnostou consultation fees and advisory boards include Roche; Industry funding: SynapDx, Sanofi-Aventis; Other funding sources include: Canadian Institutes of Health Research, Ontario Brain Institute, DOD, Autism Speaks, National Centers of Excellence, Physician Services Incorporated; Royalties received by: APPI and Springer. The remaining authors declare that they have no conflict of interest.